Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CASI Pharmaceuticals, Inc. (CASI)

2.04   0.02 (0.99%) 01-27 15:59
Open: 2.03 Pre. Close: 2.02
High: 2.05 Low: 2.015
Volume: 12,233 Market Cap: 28(M)

Technical analysis

as of: 2023-01-27 4:43:12 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.52     One year: 2.94
Support: Support1: 1.72    Support2: 1.45
Resistance: Resistance1: 2.16    Resistance2: 2.52
Pivot: 1.99
Moving Average: MA(5): 2.01     MA(20): 1.96
MA(100): 2.3     MA(250): 3.89
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 46.1     %D(3): 53.6
RSI: RSI(14): 57.6
52-week: High: 10.3  Low: 0.34
Average Vol(K): 3-Month: 33 (K)  10-Days: 28 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CASI ] has closed below upper band by 25.6%. Bollinger Bands are 79% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.05 - 2.06 2.06 - 2.07
Low: 1.99 - 2 2 - 2.01
Close: 2.03 - 2.04 2.04 - 2.05

Company Description

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Headline News

Sun, 29 Jan 2023
Solomon Islands children sing their way to safety - Solomon Islands - ReliefWeb

Wed, 25 Jan 2023
Close Up With CASI: Combatting HIV Stigma - KWQC

Tue, 24 Jan 2023
QCBJ Spotlight: CASI celebrates 50th anniversary - WHBF -

Wed, 11 Jan 2023
Close Up with CASI: Tax scams and keeping seniors safe - KWQC

Fri, 06 Jan 2023

Wed, 04 Jan 2023
Close Up With CASI: Celebrating 50 years in the Quad Cities - KWQC

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 14 (M)
Shares Float 8 (M)
% Held by Insiders 32.6 (%)
% Held by Institutions 14.8 (%)
Shares Short 205 (K)
Shares Short P.Month 91 (K)

Stock Financials

EPS -2.26
EPS Est Next Qtl 0
EPS Est This Year -0.16
EPS Est Next Year -0.19
Book Value (p.s.) 4.53
Profit Margin (%) -73.2
Operating Margin (%) -88.6
Return on Assets (ttm) -15.5
Return on Equity (ttm) -27.3
Qtrly Rev. Growth 25.8
Gross Profit (p.s.) 1.29
Sales Per Share 2.71
EBITDA (p.s.) -2.27
Qtrly Earnings Growth 0
Operating Cash Flow -28 (M)
Levered Free Cash Flow -13 (M)

Stock Valuations

PE Ratio -0.91
PEG Ratio 0
Price to Book value 0.44
Price to Sales 0.75
Price to Cash Flow -1

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.